CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 

Cumulative Syros Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

SYRS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SYRS Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -26.1 % -27.11 % -14.65 % -2.32 % 28.59 %
Y / Y Current Assets Growth -51.44 % 66 % 49.08 % 54.77 % 64.61 %
Working Capital Ratio for Trailing Twelve Months Period 5.94 6.52 5.54 4.95 4.38
Total Ranking # 546 # 540 # 755 # 977 # 1135
Seq. Current Liabilities Growth 0.07 % 20.48 % -23.48 % -19.9 % -1.29 %
Seq. Current Assets Growth -19.73 % -12.1 % -17.86 % -16.22 % 174.41 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Syros Pharmaceuticals Inc 's average Current Liabilities to $28 millions, Working Capital Ratio for Trailing Twelve Months Period to 5.94 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Syros Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about SYRS
Working Capital Ratio SYRS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 264
Sector # 479
S&P 500 # 812


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.06 5.83 3.9
(Dec 31 2017)   (Jun 30 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Fulcrum Therapeutics Inc   16.26 
Sagimet Biosciences inc   16.19 
Verve Therapeutics Inc   15.91 
Lyell Immunopharma Inc   15.88 
Ovid Therapeutics Inc   15.62 
Verona Pharma Plc  15.46 
Rallybio Corporation  15.36 
Ideaya Biosciences Inc   15.24 
Anebulo Pharmaceuticals Inc   14.89 
Olema Pharmaceuticals inc   14.82 
Cryoport inc   14.81 
Oric Pharmaceuticals Inc   14.64 
Anaptysbio Inc   14.55 
Sio Gene Therapies Inc   14.47 
Cadrenal Therapeutics Inc   14.40 
Io Biotech Inc   14.37 
Ventyx Biosciences Inc   14.29 
Cassava Sciences Inc  14.19 
Infinity Pharmaceuticals Inc   13.94 
Spruce Biosciences Inc   13.90 
Immutep Limited  13.81 
Syndax Pharmaceuticals Inc   13.74 
Rapt Therapeutics Inc   13.71 
Aerovate Therapeutics Inc   13.71 
Rani Therapeutics Holdings Inc   13.61 
Chimerix Inc   13.50 
Larimar Therapeutics Inc   13.33 
Kinnate Biopharma Inc   13.28 
Nkarta Inc   13.20 
Sensei Biotherapeutics Inc   13.11 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com